Back to top
more

Immunocore (IMCR)

(Delayed Data from NSDQ)

$35.29 USD

35.29
276,557

-0.64 (-1.78%)

Updated Oct 2, 2025 04:00 PM ET

After-Market: $34.93 -0.36 (-1.02%) 6:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.81%
2Buy17.98%
3Hold9.90%
4Sell5.43%
5Strong Sell2.74%
S&P50011.32%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth D Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (73 out of 245)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi

by Zacks Equity Research

Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.

Zacks Equity Research

Nektar Q2 Loss Narrower Than Expected, Revenues Fall Y/Y

by Zacks Equity Research

NKTR's second-quarter top and bottom lines beat estimates. Studies on the lead candidate, rezpeg, are progressing well.

Zacks Equity Research

Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus

by Zacks Equity Research

NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.

Zacks Equity Research

PBYI's Q2 Earnings Beat Estimates, Nerlynx Sales Drive Revenues

by Zacks Equity Research

Puma Biotechnology tops second-quarter earnings and revenue estimates as rising Nerlynx sales drive growth.

Zacks Equity Research

MIRM Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View

by Zacks Equity Research

Mirum surges after second-quarter earnings and revenues top estimates, driven by Livmarli growth and a raised 2025 outlook.

Zacks Equity Research

Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates

by Zacks Equity Research

VTRS beats on Q2 estimates with strength in branded drugs and growth in Greater China, lifting shares.

Zacks Equity Research

Catalyst Pharmaceuticals Q2 Earnings Beat, Firdapse Revenues Rise Y/Y

by Zacks Equity Research

CPRX beats Q2 earnings and revenue estimates as Firdapse and Agamree drive strong top-line growth.

Zacks Equity Research

Acadia Q2 Earnings Beat, Nuplazid & Daybue Sales Drive Revenue Growth

by Zacks Equity Research

ACAD reports encouraging second-quarter results as earnings and revenues beat estimates, driven by year-over-year growth in Nuplazid and Daybue sales.

Zacks Equity Research

Compared to Estimates, Immunocore (IMCR) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

While the top- and bottom-line numbers for Immunocore (IMCR) give a sense of how the business performed in the quarter ended June 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Equity Research

ADMA Beats on Q2 Earnings and Revenues, Asceniv Drives Momentum

by Zacks Equity Research

ADMA Biologics' Q2 earnings and revenue beat can be attributed to Asceniv growth. However, shares fall 7.4% in after-hours trading.

Zacks Equity Research

Novo Nordisk Q2 Earnings Beat, Sales Miss, GLP-1 Drugs Face US Hurdles

by Zacks Equity Research

NVO's Q2 earnings beat but revenues miss estimates as Wegovy and Ozempic face U.S. setbacks and rising competition.

Zacks Equity Research

HALO Stock Up on Q2 Earnings and Revenue Beat, Raised 2025 View

by Zacks Equity Research

Halozyme jumps 5.3% on second-quarter earnings and revenue beat, fueled by strong royalty growth, and a raised 2025 outlook.

Zacks Equity Research

BEAM's Q2 Loss Narrower Than Expected, Revenues Miss Mark

by Zacks Equity Research

Beam Therapeutics posts narrower second-quarter loss but misses revenue estimates. The company provides updates on pipeline progress.

Zacks Equity Research

RXRX Q2 Loss Wider Than Expected, Revenues Rise Y/Y, Stock Down

by Zacks Equity Research

Recursion Pharmaceuticals stock drops as Q2 loss widens and pipeline shake-up continues, despite revenues boost from Sanofi milestone.

Zacks Equity Research

Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y

by Zacks Equity Research

RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.

Zacks Equity Research

ESPR's Q2 Earnings & Revenues Trump Estimates, Stock Rises

by Zacks Equity Research

Esperion posts narrower-than-expected second-quarter loss with revenues rising 12% and product sales jumping 42% year over year.

Zacks Equity Research

Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut

by Zacks Equity Research

PRGO tops Q2 EPS but misses revenue; trims 2025 sales outlook, sending shares down in pre-market.

Zacks Equity Research

JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut

by Zacks Equity Research

Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.

Zacks Equity Research

ZTS Q2 Earnings & Revenues Beat Estimates, '25 Outlook Raised

by Zacks Equity Research

Zoetis posts better-than-expected Q2 results with rising sales of pet medicines, boosting its 2025 outlook.

Zacks Equity Research

TGTX Down as Q2 Earnings Miss Mark, Briumvi Sales Drive Top Line

by Zacks Equity Research

TG Therapeutics slides 18% as second-quarter earnings fall short despite a 92% revenue jump fueled by surging Briumvi sales.

Zacks Equity Research

CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption

by Zacks Equity Research

CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.

Zacks Equity Research

AXSM Q2 Loss Narrower Than Expected, Auvelity Drives Revenues Y/Y

by Zacks Equity Research

Axsome posts narrower second-quarter loss and 72% revenue surge, driven by strong Auvelity sales.

Zacks Equity Research

VRTX Q2 Earnings Beat, Stock Down as Pain Drug Misses Study Goal

by Zacks Equity Research

Vertex beats second-quarter earnings and revenue estimates, but shares slide as pain drug VX-993 misses study goal.

Zacks Equity Research

BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View

by Zacks Equity Research

BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.

Zacks Equity Research

KRYS Q2 Earnings and Sales Top Estimates, Stock Down on Q3 Outlook

by Zacks Equity Research

Krystal Biotech tops Q2 estimates with strong Vyjuvek sales, but shares fall 14% on weak Q3 revenue guidance.